Lactobacillus buchneri ameliorates obesity-related disorders induced by high-fat and high-cholesterol diet in mice

Abstract

Diet-induced obesity is a serious social issue which can cause various metabolic diseases, such as lipid metabolism disorders, chronic inflammation, and liver steatosis. Recently, probiotics have shown promise in preventing and alleviating obesity and related metabolic syndromes. Here, we investigated the effects of Lactobacillus buchneri intervention on obesity-related disorders in mice fed a high-fat and high-cholesterol diet (HFHCD). The administration of L. buchneri to the HFHCD-induced mice reduced body weight gain, fat accumulation, serum triglycerides, and total cholesterol levels. Additionally, L. buchneri treatment restored triglycerides, total cholesterol, total bile acid, aspartate aminotransferase, and alanine aminotransferase to normal levels in the liver, and ameliorated hepatic steatosis in the HFHCD-induced mice. Consistently, qPCR analysis demonstrated that L. buchneri treatment downregulated the expression of lipogenesis Dgat1 and inflammatory IL-1β in the liver. Finally, 16S rRNA gene sequencing revealed that L. buchneri treatment had a mild impact on the gut microbiota community structure, indicating that the amelioration of obesity-related disorders may not be solely attributed to gut microbiota modulation. In conclusion, these findings provide evidence that L. buchneri can be considered a probiotic to ameliorate obesity-related disorders.